CSL targets $33bn asthma market with revolutionary drug
MELBOURNE: Australia’s biggest health company CSL is aiming to crack the $US21.6bn ($33.54bn) asthma market,
MELBOURNE: Australia’s biggest health company CSL is aiming to crack the $US21.6bn ($33.54bn) asthma market,